<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01424163</url>
  </required_header>
  <id_info>
    <org_study_id>223HV101</org_study_id>
    <nct_id>NCT01424163</nct_id>
  </id_info>
  <brief_title>Dexpramipexole Japanese PK Study</brief_title>
  <official_title>A Single and Multiple Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Dexpramipexole (BIIB050) in Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Knopp Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Knopp Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single and multiple dose, open-label study to evaluate the pharmacokinetics (PK),&#xD;
      safety, and tolerability of dexpramipexole administered orally to adult Japanese and&#xD;
      Caucasian healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to evaluate the influence of ethnic factors on dexpramipexole safety,&#xD;
      tolerability, and PK. Subjects will be admitted to the clinical unit on Day -1 (the day prior&#xD;
      to first dosing) and will remain in the clinical unit under observation until discharge. All&#xD;
      subjects will have a final follow up visit. Whilst resident in the clinic, subjects will&#xD;
      receive 4 treatments: The first 3 treatments comprise Part A of the study and the final&#xD;
      treatment group comprises Part B.&#xD;
&#xD;
      Part A:&#xD;
&#xD;
      Treatment 1: Dose 1 (reduced) of dexpramipexole; a single dose Treatment 2: Dose 2 (standard)&#xD;
      dexpramipexole; a single dose Treatment 3: Dose 3 (standard) dexpramipexole; 5 doses&#xD;
      administered at 12 hour intervals Part B: Dose 4 (standard) dexpramipexole; 5 doses&#xD;
      administered at 12 hour intervals There will be a minimum washout of 3 days between&#xD;
      treatments.&#xD;
&#xD;
      For all subjects, prior to proceeding to the next treatment group, safety and tolerability&#xD;
      data will be reviewed.&#xD;
&#xD;
      Caucasian subjects will be matched individually (on a 1:1 basis) to Japanese subjects with&#xD;
      respect to gender and age and if possible BMI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of dexpramipexole</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours after dosing on Days 1 and 5 in Treatments 1 and 2, and after the fifth dose on Day 11 in Treatment 3 for Parts A &amp; B.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of dexpramipexole</measure>
    <time_frame>pre-dose and at 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours after dosing on Days 1 and 5 in Treatments 1 and 2, and after the fifth dose on Day 11 in Treatment 3 for Parts A &amp; B.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in clinical laboratory tests</measure>
    <time_frame>pre-dose to 72 hrs post-dose in each dose group and again at follow-up (14 hrs post last dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG changes</measure>
    <time_frame>pre-dose to 72 hrs post-dose in each dose group and again at follow-up (14 hrs post last dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Sign changes</measure>
    <time_frame>pre-dose to 72 hrs post-dose in each dose group and again at follow-up (14 hrs post last dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event monitoring</measure>
    <time_frame>pre-dose to 72 hrs post-dose in each dose group and again at follow-up (14 hrs post last dose)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Treatment 1 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexpramipexole single dose (reduced dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 2 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexpramipexole single dose (Standard dose)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment 3 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexpramipexole multiple dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment for Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexpramipexole multiple dosing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single dose reduced</intervention_name>
    <description>Treatment 1 (Part A)</description>
    <arm_group_label>Treatment 1 (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single dose standard</intervention_name>
    <description>Treatment 2 (Part A)</description>
    <arm_group_label>Treatment 2 (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple Dose</intervention_name>
    <description>Treatment 3 (Part A)</description>
    <arm_group_label>Treatment 3 (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple Dose</intervention_name>
    <description>Part B</description>
    <arm_group_label>Treatment for Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who are able and willing to give written informed consent.&#xD;
&#xD;
          -  Adult Japanese and Caucasian males/females aged 18 to 60 years inclusive and between&#xD;
             18 and 30 kg/m2 body mass index (BMI), inclusive.&#xD;
&#xD;
          -  Male and female subjects will be enrolled on the study. Male subjects and female&#xD;
             subjects of childbearing potential, must practice effective contraception during the&#xD;
             study and be willing and able to continue contraception for 1 month (females) or 3&#xD;
             months (males) after their last dose of study treatment&#xD;
&#xD;
          -  Japanese subjects must be born in Japan and have both parents and four grandparents of&#xD;
             Japanese descent.&#xD;
&#xD;
          -  Japanese subjects must have lived outside of Japan for no more than 5 years.&#xD;
&#xD;
          -  Japanese subjects must not have significant changes with regard to diet; i.e., their&#xD;
             diet must not have significantly changed since leaving Japan.&#xD;
&#xD;
          -  Caucasian subjects will be matched individually (on a 1:1 basis) to Japanese subjects&#xD;
             with respect to gender and age, and if possible BMI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who do not conform to the above inclusion criteria.&#xD;
&#xD;
          -  Female subjects who are pregnant, trying to become pregnant or lactating.&#xD;
&#xD;
          -  Subjects who have a clinically relevant history or presence of respiratory,&#xD;
             gastrointestinal, renal, hepatic, hematological, lymphatic, neurological,&#xD;
             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,&#xD;
             dermatological, connective tissue diseases or disorders.&#xD;
&#xD;
          -  Subjects who have a clinically relevant surgical history.&#xD;
&#xD;
          -  Subjects who have previously received dexpramipexole or pramipexole.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>July 28, 2011</study_first_submitted>
  <study_first_submitted_qc>August 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2011</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

